Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring

Study Overview
=================
Brief Summary
-----------------
The study is focused on the investigation of possible associations between plasma/serum levels of agouti related peptide (AgRP) and its genetic background in healthy women with physiological pregnancy (non-preeclamptic) and women with preeclampsia, in the postpartum period, and in their offspring.

Detailed Description
-----------------
The study is focused on investigation of possible genotype-phenotype interactions of agouti-related peptide (AgRP) in postpartum non-preeclamptic women and preeclamptic women and in their offspring.

Official Title
-----------------
Genotype-phenotype Associations of Agouti-related Peptide (AgRP) in Postpartum Period in Preeclamptic and Non-preeclamptic Women and Their Offspring

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For preeclampsia: development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h) single-fetus pregnancy age range 18-35 y no preconceptional history of hypertension For mother with physiological pregnancies: uncomplicated spontaneous conception single-fetus pregnancy age range 18-35 y spontaneous uncomplicated delivery no history of preconceptional hypertension Exclusion Criteria: For preeclampsia: multiple pregnancy preeclampsia superimposed to chronic hypertension preceding pregnancy kidney disease fetal malformations For mothers with physiological pregnancies: in vitro fertilization fetal malformations multiple pregnancy events of bleeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mothers, preeclampsia<br>Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h). | |
| Newborns, physiological pregnancy-delivery<br>The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery. | |
| Newborns, pregnancy with preeclampsia<br>Newborns from the pregnancies complicated by preeclampsia. | |
| Mothers, Physiological pregnancy-labour<br>The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma/serum level of agouti/related peptide in peripheral blood in postpartum mother |  | 2-4 hours postpartum | 
| Plasma level of agouti-related peptide in umbilical cord blood from the newborn |  | immediately postpartum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| maternal weight gain during pregnancy |  | using postpartum and peripartum data | 
| birth weight of the newborn |  | immediately postpartum | 
| maternal preconceptional BMI |  | anamnestic information | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
preeclampsia, agouti-related peptide, intrauterine growth, birth weight, Intrauterine growth restriction due to preeclampsia